Abstract

Acanthosis Nigricans (AN), on the other hand, is known to be a benign dermatosis, which has hyperpigmented and velvet-like lesions of skin folds. However, taking AN into consideration from an aesthetic point of view may lead one to overlook essential aspects and vulnerabilities. The current paper reinterprets AN as a profound aesthetic sentinel a “cutaneous window” through which a patient’s underlying asymptomatic abnormalities can be seen. Based on the common pathophysiologic principles, the article gives insight into the mechanisms of benign and malignant AN occurrence. The main feature in benign AN is hyperinsulinemia, where excess insulin in the blood cross-reacts with insulinlike growth factor-1 (IGF-1) receptors on keratinocytes and fibroblasts, resulting in cell proliferation. Such a phenomenon acts as an early indicator of metabolic syndrome, type 2 diabetes mellitus, polycystic ovary syndrome (PCOS), and many endocrinopathies. On the contrary, malignant AN, typically occurring suddenly and intensely, is caused by growth factors secreted by tumours (for example, TGF-alpha). In addition, different familial forms demonstrate links to particular genetic mutations. By distinguishing such presentations, it is possible to determine whether AN is caused by metabolic disorders or paraneoplastic phenomena. Finally, this review underlines the key role played by primary care providers and dermatologists in the process of deciphering these skin manifestations. Instead of viewing AN simply as a dermatological condition, it should be used as a diagnostic opportunity for systematic screening of the whole body. Early identification of the causative agent of AN leads to prompt treatment and helps turn the patient’s fate towards the positive direction.

• 1.   Rościszewska A, Adamski Z, Żaba R, Bowszyc-Dzikowska M. The importance and challenges of early diagnosis of paraneoplastic skin syndromes in cancer detection: a review. Cancers (Basel). 2025;17(7):1053. doi:10.3390/ cancers17071053.
• 2.   Zeng J, Li Y, Zhou L, Gao L, Huang J, Tong X, Zhao Y, Lu T, Fu Z, Tan L. Clinical insights into the pathogenesis and treatment strategies of acanthosis nigricans: a bibliometric study of current trends and future directions. Clin Cosmet Investig Dermatol. 2026;19:572050. doi:10.2147/CCID.S572050.
• 3.   Sibarani BLA, Utami P. Diagnosis and management of acanthosis nigricans: literature review. Cermin Dunia Kedokt. 2026;53(4):266- 272. doi:10.55175/cdk.v53i04.1667.
• 4.   Sado A, Tomaszewska M, Wójcik S, Rulkiewicz A. Skin as a metabolic organ: dermatologic markers of morbid obesity and their role in risk stratification and treatment monitoring. Diagnostics (Basel). 2026;16(9):1314. doi:10.3390/diagnostics16091314.
• 5.   Zeng J, Li Y, Zhou L, Gao L, Huang J, Tong X, et al. Clinical insights into the pathogenesis and treatment strategies of acanthosis nigricans: a bibliometric study of current trends and future directions. Clin Cosmet Investig Dermatol. 2024;19:572-585.
• 6.   Nandkeoliar MK, Goyal R, Saxena R. Cardiometabolic profile status in diabetic children and adolescents. Sch J Appl Med Sci. 2017;5(10A):3843-3847.
• 7.   Didona D, Rallo A, Carugno A, Paolino G. Paraneoplastic dermatoses: a clue for underlying malignancies. J Clin Med. 2025;14(3):1014. doi:10.3390/jcm14031014.
• 8.   Parmar BV, Pala N. A cross-sectional analytical study of morphological patterns of acanthosis nigricans and its association with components of metabolic syndrome. Curr Med Issues. 2024;22(3):140-145. doi:10.4103/cmi. cmi_20_24.
• 9.   Dhanoo AS, Ramroach SK, Hill-Briggs F, Cockburn BN. Grading acanthosis nigricans using a smartphone and color analysis: a novel noninvasive method to screen for impaired glucose tolerance and type 2 diabetes. Diabetes Spectr. 2024;37(2):139-148. doi:10.2337/ ds23-0042.
• 10.   Tyebkhan G, Velaskar S, Yadav P, Phiske M, Shah D. An Indian expert group review of acanthosis nigricans with recommendations for early detection and timely management. J Assoc Physicians India. 2024;72(6):74-84. doi:10.59556/japi.72.0569.
• 11.   Barnawal P, Bhandari S, Shrestha S, et al. Malignant acanthosis nigricans and tripe palms: cutaneous indicators of gastric carcinoma resolution: a case report. Medicine (Baltimore). 2025;104(3):e41181. doi:10.1097/ MD.0000000000041181.
• 12.   Bharati B, Sarkar R, Garg T, Goyal R, Mendiratta V. Efficacy of 15% trichloroacetic acid peel versus 35% glycolic acid peel in acanthosis nigricans: a randomized open-label study. J Cutan Aesthet Surg. 2024;17(2):94-99. doi:10.4103/jcas_jcas_76_23.
• 13.   Kotekar S, Thappa DM. Facial dyschromias: a review of clinical and dermoscopic features. Cosmoderma. 2024;4:130. doi:10.25259/ CSDM_156_2024.
• 14.   American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49 (Suppl 1):S12-S28. doi:10.2337/dc26-S002.
• 15.   Parmar S, Guleria P, Jindal S, Ashawat MS, Kumar P. A comprehensive review of acanthosis nigricans: pathogenesis, clinical manifestation and management. Recent Adv Inflamm Allergy Drug Discov. 2025;19(2): 135-145. doi:10.2174/0127722708314530240919 054410.
• 16.   Alamri A, Alraddadi RA, Alzahrani D, Abualola AH, Maaddawi HA, Alharthy RF, Alkhashan AY, Ashqan MY, Shaheen EA, Almahdi B, Althobaiti HM. The efficacy of topical treatments for acanthosis nigricans: a systematic review of randomized controlled trials. Front Med (Lausanne). 2025;12:1641322. doi:10.3389/fmed.2025.1641322.

Data Sharing Statement

Funding